Products

Earnings
API

Get in Touch

Contact Us
X (Twitter)
LinkedIn

Resources

Disclaimer: CapyFin provides financial data and AI analysis for informational purposes only and does not provide investment advice or recommendations. Real-time data and AI outputs may be inaccurate, incomplete, delayed, or contain errors or hallucinations. Investing involves risk, including loss of principal. The service is provided “as is” and we disclaim liability to the fullest extent permitted by law. See our Terms of Service and Privacy Policy.

Akero Fiscal Q1 2021 Earnings Report - CapyFin

Akero

AKRO · NASDAQ🇺🇸

View Company

Overview Earnings

Dividends Seasonality Metrics

Q3 2025 +0.20%Q2 2025 +0.08%Q1 2025 +4.30%Q4 2024 +2.87%Q3 2024 -5.25%Q2 2024 -2.97%Q1 2024 -0.87%Q4 2023 +2.13%Q3 2023 +5.30%Q2 2023 +6.16%Q1 2023 +0.15%Q4 2022 -4.10%Q3 2022 -6.81%Q2 2022 +18.38%Q1 2022 -11.39%Q4 2021 -1.94%Q3 2021 +4.56%Q2 2021 +0.97%Q1 2021 +2.58%Q4 2020 -1.06%Q3 2020 -3.02%Q2 2020 -0.92%Q1 2020 +2.83%Q4 2019 -20.89%Q3 2019 -3.77%Q2 2019 +1.27%Q1 2019 Q4 2018 Q3 2018 Q2 2018 Q1 2018 Q4 2017

May 13, 2021

•

Mar 31, 2021

Akero Q1 2021 Earnings Report

Akero Therapeutics reported first quarter financial results.

Key Takeaways

Akero Therapeutics reported its first quarter financial results, highlighting continued progress in developing treatments for non-alcoholic steatohepatitis (NASH).

Continued building on the strong foundation from the Phase 2a BALANCED main study.

New data showed signs of reversing fibrosis in biopsy-confirmed F4 NASH patients with compensated cirrhosis after 16 weeks of treatment.

Initiated two parallel, separate Phase 2b clinical trials in F2-F3 and F4 NASH this year.

Expect to begin reporting data in the third quarter of 2022.

EPS

-$0.43

Previous year: -$0.42

+2.4%